Qualitative and Quantitative Optimization of FOXE1 Gene Polymerase Chain Reaction Product as a GC-Rich Gene

Document Type : Original Article(s)

Authors

1 MSc, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences AND Iranian Cancer Control and Prevention Center, Isfahan, Iran

3 PhD, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Approximately 3% of the human genome is rich in GCs. These regions are often found in the promoter of genes, especially housekeeping genes and tumor suppressor genes. Amplification of these GC-rich regions can be challenging. Because the stability of GC-rich DNA sequences is higher, secondary structures are easily formed in these regions. Type 4 non-medullary thyroid carcinoma has been linked to the FOXE1 gene as a risk factor. FOXE1 belongs to a large family of transcription factors principal for the development of the thyroid gland's morphology.
Methods: With a high proportion of GC, a portion of the FOXE1 gene sequence cannot be amplified using the usual polymerase chain reaction. This work is an experimental study that deals with this issue.
Findings: The results of the present study showed that the Touchdown polymerase chain reaction, in combination with CO-amplification materials such as betaine and Dimethyl Sulfoxide (DMSO), is effective in amplifying the sequence of this region of the FOXE1 gene by destruction of the secondary structures formed in the sequence and increasing the reaction product.
Conclusion: Using this method, GC-rich regions in additional genes with a similar degree of GC as the FOXE1 gene can be amplified.

Highlights

Zohreh Mohammadi Zanian: PubMed

Mehrdad Zeinalian: Google Scholar, PubMed

Mohammad Amin Tabatabaiefar: Google Scholar, PubMed

Keywords

Main Subjects

References

  1. Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am 2019; 48(1): 23-35.
  2. Global Cancer Obseratory (gco). [Online]. [cited 2020]; Available from: URL: https://gco.iarc.fr/
  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
  4. Chrisoulidou A, Boudina M, Tzemailas A, Doumala
    E, Iliadou PK, Patakiouta F, et al. Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer. Thyroid Res 2011; 4(1): 1-5.
  5. Landa I, Ruiz-Llorente S, Montero-Conde C, Inglada-Pérez L, Schiavi F, Leskelä S, et al. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Gene. 2009; 5(9): e1000637.
  6. Wiese S, Emmerich D, Schröder B, Murphy DB,
    Grzeschik KH, Van Kessel AG, et al. The novel human UNF-3/fork head-like 5 gene: Chromosomal localization and expression pattern. DNA Cell Biol 1997; 16(2): 165-71.
  7. Venza I, Visalli M, Teti D, Venza M. FOXE1 (forkhead box E1 (thyroid transcription factor 2)). Atlas of Genetics and Cytogenetics in Oncology and Haematology; 2011. p. 182.
  8. Cuesta I, Zaret KS, Santisteban P. The forkhead factor FoxE1 binds to the thyroperoxidase promoter during thyroid cell differentiation and modifies compacted chromatin structure. Mol Cell Biol 2007; 27(20): 7302-14.
  9. Fernandez LP, Lopez-Marquez A, Martinez AM, Gomez-Lopez G, Santisteban P. New insights into FoxE1 functions: identification of direct FoxE1 targets in thyroid cells. PLoS One 2013; 8(5): e62849.
  10. Bullock M, Duncan EL, O’Neill C, Tacon L, Sywak M, Sidhu S, et al. Association of FOXE1 polyalanine repeat region with papillary thyroid cancer. J Clin Endocrinol Metab 2012; 97(9): E1814-9.
  11. Gibbs RA. DNA amplification by the polymerase chain reaction. Anal Chem 1990; 62(13): 1202-14.
  12. Varadaraj K, Skinner DM. Denaturants or cosolvents improve the specificity of PCR amplification of a G + C-rich DNA using genetically engineered DNA polymerases. Gene 1994; 140(1): 1-5.
  13. McDowell DG, Burns NA, Parkes HC. Localised sequence regions possessing high melting temperatures prevent the amplification of a DNA mimic in competitive PCR. Nucleic Acids Res 1998; 26(14): 3340-7.
  14. Kool ET. Hydrogen bonding, base stacking, and steric effects in DNA replication. Annu Rev Biophys
    Biomol Struct 2001; 30(1): 1-22.
  15. Sahdev S, Saini S, Tiwari P, Saxena S, Saini KS. Amplification of GC-rich genes by following a combination strategy of primer design, enhancers and modified PCR cycle conditions. Mol Cell Probes 2007; 21(4): 303-7.
  16. Bachmann HS, Siffert W, Frey UH. Successful amplification of extremely GC-rich promoter regions using a novel ‘slowdown PCR’technique. Pharmacogenetics 2003; 13(12): 759-66.
  17. Hubé F, Reverdiau P, Iochmann S, Gruel Y. Improved PCR method for amplification of GC-rich DNA sequences. Mol Biotechnol 2005; 31: 81-4.
  18. Suguna S, Nandal DH, Kamble S, Bharatha A, Kunkulol R. Genomic DNA isolation from human whole blood samples by non enzymatic salting out method. Int J Pharm Pharm Sci 2014; 6(6): 198-9.
  19. Gellert M, Lipsett MN, Davies DR. Helix formation by guanylic acid. Proc Natl Acad Sci U S A 1962; 48(12): 2013-8.
  20. Zhang Z, Yang X, Meng L, Liu F, Shen C, Yang W. Enhanced amplification of GC-rich DNA with two organic reagents. Biotechniques 2009; 47(3): 775-9.
  21. Zhou M, Hatahet Z. An improved ligase-free method for directional subcloning of PCR amplified DNA. Nucleic Acids Res 1995; 23(6): 1089-90.
  22. Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. ’Touchdown’PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 1991; 19(14): 4008.
  23. Duckworth AW, Rule SAJ. The use of ‘touchdown’polymerase chain reaction increases the sensitivity and specificity of t (11; 14)(q13; q32) detection in patients with mantle cell lymphoma. Br J Haematol 2003; 121(6): 952-3.
Journal of Isfahan Medical School
Volume 41, Issue 743
3rd Week, January
January and February 2024
Pages 1004-1010

Files

History

  • Receive Date: 12 July 2023
  • Accept Date: 17 January 2024

Share

How to cite

Statistics